Ardea Biosciences, Inc. (RDEA)

[surf1944]

Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
Thursday September 11, 8:00 am ET

SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA - News) today announced that preclinical data will be presented on the Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, at the 20th European Organisation for Research and Treatment of Cancer (EORTC) -- National Cancer Institute (NCI) -- American Association for Cancer Research (AACR) symposium on 'Molecular Targets and Cancer Therapeutics' in Geneva, Switzerland.

The presentation details are as follows:

Date/Time: Friday, October 24 from 12:00 p.m. - 2:00 p.m. CEST
Abstract Title: "Selective MEK Inhibitor RDEA119 exhibits efficacy in
orthotopic hepatoma models and cytostatic potential in
multiple cell based models of cancer"
Abstract: 577
Session Title: Signal Transduction Modulators
Location: Poster Hall, GenevaPalExpo